 DALLAS and BALTIMORE, Aug. 19, 2021 PRNewswire -- Lantern Pharma NASDAQ: LTRN, a clinical stage biopharmaceutical company, announced today that a successful preclinical study has shown its drug candidate LP-184 is able to inhibit tumor growth and improve survival in animal models of glioblastoma GBM. This study was conducted in collaboration with the research group of John Laterra, M.D. 